Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Medtech Ventures | Aneurysm Flow Modulating Device Market

Current Status and Strategic Opportunities

Aneurysm Flow Modulating Device Market Current Status and Strategic Opportunities

With ev3 valuing Chestnut Medical Pipeline Embolization Device Technology at $150 million and forecasting a market of $350 million for cerebral flow diversion devices by 2013, the floodgates for innovation in the paradigm-shifting field of aneurysm flow modulation have just been blown away.

The unmet medical need is vast, from difficult to coil wide-necked cerebral aneurysms to hard-to-repair thoraco-abdominal aortic aneurysms, and the technology is proving itself to be safe, logical and accessible to small & medium size entrepreneurial start-ups.

Endovascular treatment of aneurysms has evolved substantially over the past two decades, transitioning from an investigational therapy into routine clinical practice and ultimately emerging as the treatment of choice for many lesions.

To date, endovascular therapy has been almost exclusively focused on filling the aneurysm sac with embolic material (coils or liquid embolics) or bridging the aneurysm with a covered stent (Stent Graft).

The idea behind the use of endovascular flow modulating (diverting) devices as monotherapy for endovascular aneurysm repair stems from the concept that a low porosity stent bridging the aneurysm neck modulates hemodynamic flow away from the vortex and streamlines blood flow within parent artery.

Dedicated flow diverting devices for eliminating cerebral aneurysms from circulation without the need for coils have already been cleared for marketing in Europe since mid-2008 and dedicated flow modulating devices for peripheral aneurysm repair entered the European market in 2009.

The market for aneurysm flow modulating devices is still in the embryonic stage with windows of opportunities opening for early entrants. Due to the novelty of the paradigm-shifting technology, little notice was taken of the market potential by large multinationals until ev3 adopted, and started publicizing the technology.

The hypothesis that wall shear stress modulates endothelial cellularity is gaining increasing support from researchers in the field. However, few companies are currently developing dedicated flow modulating devices with designs that take into consideration hemodynamic flow and endothelial growth dynamics.

Medtech Ventures' Aneurysm Flow Modulating Device Market - Current Status & Strategic Opportunities is the first report to cover the market of flow-diverting devices for aneurysm reconstruction and repair.

The report is an exclusive introduction to this emerging market and provides a thorough, analysis of both the technology and markets with analysis of existing markets for cerebral, abdominal aortic, thoracic aortic and peripheral aneurysms, profiles of leading participants and forecasts to the year 2015.

With Aneurysm Flow Modulating Device Market - Current Status & Strategic Opportunities, you'll be able to better:

- Assess market size and growth potential for aneurysm flow diverting devices.

- Identify emerging technologies and the companies behind them.

- Leverage your own technology and brainstorm new business opportunities.

- Understand current market dynamics, competitors' positions and market shares.

Report Code: MV09081

Report Publisher: Medtech Ventures

Date Published: August 2009

Number of Pages: 80

Table of Contents
Price: $6,950.00 / €4,645.38

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions